|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:acquiredBy
|
gptkb:BlueGnome
gptkb:Edico_Genome
gptkb:Epicentre_Biotechnologies
gptkb:Grail,_Inc.
gptkb:Helixis
gptkb:Verinata_Health
Enancio
|
|
gptkbp:CEO
|
gptkb:Jacob_Thaysen
|
|
gptkbp:CUSIP
|
452327109
|
|
gptkbp:foundedYear
|
April 1998
|
|
gptkbp:founder
|
gptkb:Anthony_A._Czarnik
gptkb:Anthony_Czarnik
gptkb:John_Stuelpnagel
gptkb:Larry_Bock
gptkb:Mark_Chee
gptkb:David_Walt
|
|
gptkbp:headquartersLocation
|
gptkb:San_Diego,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Illumina, Inc.
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:ISIN
|
US4523271090
|
|
gptkbp:keyPerson
|
gptkb:Francis_deSouza
gptkb:Jacob_Thaysen
gptkb:Jay_Flatley
|
|
gptkbp:logo
|
Illumina logo.svg
|
|
gptkbp:marketCap
|
~$25 billion (2024)
|
|
gptkbp:netIncome
|
-$1.6 billion (2023)
|
|
gptkbp:notableProduct
|
gptkb:BaseSpace_Sequence_Hub
gptkb:DRAGEN_Bio-IT_Platform
gptkb:HiSeq
gptkb:Infinium_Assay
gptkb:MiSeq
gptkb:NextSeq
gptkb:Nextera
gptkb:NovaSeq
gptkb:TruSeq
gptkb:iSeq
|
|
gptkbp:numberOfEmployees
|
approximately 9,100 (2023)
|
|
gptkbp:products
|
gene expression
DNA sequencing
genotyping
personal genomics
|
|
gptkbp:revenue
|
$4.5 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ-100
gptkb:S&P_500
|
|
gptkbp:stockSymbol
|
gptkb:ILMN
|
|
gptkbp:subsidiary
|
gptkb:Grail,_Inc.
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:_ILMN
|
|
gptkbp:type
|
public
|
|
gptkbp:website
|
https://www.illumina.com/
|
|
gptkbp:bfsParent
|
gptkb:Frances_Arnold
|
|
gptkbp:bfsLayer
|
4
|